Dr. Hooman Djaladat (@hoomandjaladat) 's Twitter Profile
Dr. Hooman Djaladat

@hoomandjaladat

Professor of Urology, Urologic oncologist specializing in bladder,prostate,kidney,testicular cancer using MIS technique @keckmedusc. ❤️👨‍👩‍👧‍👦🚴‍♂️🎬✈️🏖️

ID: 794744723235696644

linkhttps://providers.keckmedicine.org/provider/Hooman+Djaladat/205577 calendar_today05-11-2016 03:34:42

156 Tweet

1,1K Takipçi

1,1K Takip Edilen

Alireza Ghoreifi, MD (@alirezaghoreifi) 's Twitter Profile Photo

Had the privilege of presenting two abstracts at ASCO #GU24 🩸Single-stage retrocrural and retroperitoneal LND in GCTs, led by Sia Daneshmand, M.D. 🧬Updated data on the use of liquid biopsy in UTUC, led by Dr. Hooman Djaladat and Peter Kuhn USC Urology USC Michelson CSI-Cancer

Had the privilege of presenting two abstracts at <a href="/ASCO/">ASCO</a> #GU24 
🩸Single-stage retrocrural and retroperitoneal LND in GCTs, led by <a href="/siadaneshmand/">Sia Daneshmand, M.D.</a> 
🧬Updated data on the use of liquid biopsy in UTUC, led by <a href="/Hoomandjaladat/">Dr. Hooman Djaladat</a> and <a href="/pkuhn1/">Peter Kuhn</a>
<a href="/USC_Urology/">USC Urology</a> <a href="/uscmichelsoncsi/">USC Michelson CSI-Cancer</a>
DrBagrodia (@adityabagrodia) 's Twitter Profile Photo

•🤖 R-RPLND ->lower blood loss & shorter hospital stays. •⚖️ Similar relapse rates between R-RPLND & O-RPLND. •🕒 Longer OR for R-RPLND, but with low morbidity. pubmed.ncbi.nlm.nih.gov/38278693/ Rob Hamilton Dr. John Sfakianos Dr. Hooman Djaladat Phillip Pierorazio Scott Eggener nirm

Alireza Ghoreifi, MD (@alirezaghoreifi) 's Twitter Profile Photo

🔥Happy to share our recent Urologic Oncology paper 1️⃣Dx: CTCts and oncosomes are detectable in UTUC PBSs at higher levels than normals 2️⃣FU: 6 analytes exhibit sig decrease after surgery 3️⃣Prognosis: CK|CD oncosomes and D|CK|V cells can predict recurrence 🔗tinyurl.com/3jr5wrx2

🔥Happy to share our recent <a href="/UrolOncol/">Urologic Oncology</a> paper

1️⃣Dx: CTCts and oncosomes are detectable in UTUC PBSs at higher levels than normals

2️⃣FU: 6 analytes exhibit sig decrease after surgery 

3️⃣Prognosis: CK|CD oncosomes and D|CK|V cells can predict recurrence

🔗tinyurl.com/3jr5wrx2
Alireza Ghoreifi, MD (@alirezaghoreifi) 's Twitter Profile Photo

🔥Just published online ▶️ 2111 pts: 967 ERAS and 1144 non-ERAS 🩸Better perioperative outcomes (EBL, Transfusion, LOS) with ERAS 🎗️ERAS showed no significant impact on OS and RFS Runzhuo Ma Farshad Sheybaee Moghaddam Dr. Hooman Djaladat USC Urology ERAS® Society 🔗sciencedirect.com/science/articl…

🔥Just published online
▶️ 2111 pts: 967 ERAS and 1144 non-ERAS
🩸Better perioperative outcomes (EBL, Transfusion, LOS) with ERAS
🎗️ERAS showed no significant impact on OS and RFS
<a href="/Runzhuo_Ma/">Runzhuo Ma</a> <a href="/FarshadSheybaee/">Farshad Sheybaee Moghaddam</a> <a href="/Hoomandjaladat/">Dr. Hooman Djaladat</a> <a href="/USC_Urology/">USC Urology</a> <a href="/ErasSociety/">ERAS® Society</a> 
🔗sciencedirect.com/science/articl…
Farshad Sheybaee Moghaddam (@farshadsheybaee) 's Twitter Profile Photo

Just Started #AUA2024: 🎯IVC resection: Main concurrent vascular procedure 🎯Correlated w/ great vessel resection: pre-chemo IVC diameter, Circumferential contact of dominant mass with IVC, post-chemo IVC thrombosis. Dr. Hooman Djaladat Sia Daneshmand, M.D. Alireza Ghoreifi, MD USC Urology

Just Started #AUA2024:

🎯IVC resection: Main concurrent vascular procedure

🎯Correlated w/ great vessel resection: pre-chemo IVC diameter, Circumferential contact of dominant mass with IVC, post-chemo IVC thrombosis.
<a href="/Hoomandjaladat/">Dr. Hooman Djaladat</a> <a href="/siadaneshmand/">Sia Daneshmand, M.D.</a> <a href="/alirezaghoreifi/">Alireza Ghoreifi, MD</a> <a href="/USC_Urology/">USC Urology</a>
Alireza Ghoreifi, MD (@alirezaghoreifi) 's Twitter Profile Photo

Thank you for highlighting our study. Analysis after propensity score matching of MIS vs open Nx post-IO groups: ⬇️lower EBL, intra-op transfusion, LOS, and ICU admission ➡️Simillar 90-day complications and readmissions Dr. Hooman Djaladat USC Urology #AUA24

Thank you for highlighting our study. 

Analysis after propensity score matching of MIS vs open Nx post-IO groups:
⬇️lower EBL, intra-op transfusion, LOS, and ICU admission 
➡️Simillar 90-day complications and readmissions 

<a href="/Hoomandjaladat/">Dr. Hooman Djaladat</a> <a href="/USC_Urology/">USC Urology</a> #AUA24
UroToday.com (@urotoday) 's Twitter Profile Photo

Outcomes of minimally invasive nephrectomy following immune-checkpoint inhibitor therapy: Data from a multicenter study. Presentation by Alireza Ghoreifi, MD USC Urology. #AUA24 written coverage by Julian Chavarriaga University of Toronto > bit.ly/3y42LtP

Outcomes of minimally invasive nephrectomy following immune-checkpoint inhibitor therapy: Data from a multicenter study. Presentation by <a href="/alirezaghoreifi/">Alireza Ghoreifi, MD</a> <a href="/USC_Urology/">USC Urology</a>. #AUA24 written coverage by <a href="/chavarriagaj/">Julian Chavarriaga</a> <a href="/UofT/">University of Toronto</a> &gt; bit.ly/3y42LtP
Farshad Sheybaee Moghaddam (@farshadsheybaee) 's Twitter Profile Photo

Thrilled to present at the great session led by Dr. Griebling (Tomas L. Griebling ), Brian Keith McNeil , and Dr. Lange on Health Equity & outcomes: 🎯 High Socioeconomic Deprivation ⬇ #UTUC Overall Survival 🎯 Insurance type🔗Follow-up Length Dr. Hooman Djaladat Jamal Nabhani USC Urology

Thrilled to present at the great session led by Dr. Griebling (<a href="/GeroUroTLG/">Tomas L. Griebling</a> ), <a href="/Dr_Brian_McNeil/">Brian Keith McNeil</a> , and Dr. Lange on Health Equity &amp; outcomes:  
🎯 High Socioeconomic Deprivation ⬇ #UTUC Overall Survival  
🎯 Insurance type🔗Follow-up Length
<a href="/Hoomandjaladat/">Dr. Hooman Djaladat</a>  <a href="/jnabhani/">Jamal Nabhani</a> <a href="/USC_Urology/">USC Urology</a>
Alireza Ghoreifi, MD (@alirezaghoreifi) 's Twitter Profile Photo

Our PUBMIC trial has been published in the June issue of Journal of Urology. It is featured on the cover page and highlighted as the Editor's Choice by Rob Siemens. Dr. Hooman Djaladat USC Urology 🔗auajournals.org/doi/10.1097/JU…

Our PUBMIC trial has been published in the June issue of <a href="/JUrology/">Journal of Urology</a>. It is featured on the cover page and highlighted as the Editor's Choice by <a href="/siemensr/">Rob Siemens</a>. 
<a href="/Hoomandjaladat/">Dr. Hooman Djaladat</a> <a href="/USC_Urology/">USC Urology</a> 
🔗auajournals.org/doi/10.1097/JU…
Alireza Ghoreifi, MD (@alirezaghoreifi) 's Twitter Profile Photo

🔥 Our Words of Wisdom in European Urology reply to the paper by Julian Chavarriaga et al, discussing the evolution of PC-RPLND techniques over time and outcomes of robotic approach. James Porter Dr. Hooman Djaladat USC Urology 🔗Free access link: authors.elsevier.com/c/1jXA114kplyy…

🔥 Our Words of Wisdom in <a href="/EUplatinum/">European Urology</a> reply to the paper by <a href="/chavarriagaj/">Julian Chavarriaga</a> et al, discussing the evolution of PC-RPLND techniques over time and outcomes of robotic approach. 
<a href="/JamesPorterMD/">James Porter</a> <a href="/Hoomandjaladat/">Dr. Hooman Djaladat</a> <a href="/USC_Urology/">USC Urology</a> 

🔗Free access link: authors.elsevier.com/c/1jXA114kplyy…